Civilian anger! Gilead voluntarily applied to disqualify Redsyway orphan drug and give up interest
-
Last Update: 2020-05-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On March 26, Gilead Sciences filed an application with the FDA to revoke remdesivir's eligibility for the treatment of COVID-19 and waive all preferential benefits associated with that qualificationearly March, Gilead Sciences sought the FDA's eligibility for Redsey as an orphan drug for COVID-19 potential therapiesOn March 24, Beijing time, the FDA granted Theridsiwe Orphan Drug a license for the treatment of COVID-19However, as soon as the news broke, it caused a lot of controversy and doubt, some in the industry worried that the eligibility of orphan drugs may affect Thewe's accessibility, and some people directly criticized Gilead's monopoly on the current COVID-19 pandemicfaced questions, Gilead urgently applied for the disqualificationGilead said in a statement that the company recognizes the urgent public health needs of the COVID-19 pandemic and is moving forward with the development of RedseyGilead also said he was confident that the Redsiewe regulatory review process would be able to be completed at an accelerated rate without the availability of orphan drugs, Gilead is currently working on six clinical trials to evaluate the efficacy of Redcywe's treatment of COVID-19 patientsOf these, two clinical trials in China are expected to be completed in Aprilreference source: Gilead asks FDA to rescind remdesivir orphan drug tag after after public
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.